Lehner, Anja; Dashkalova, Tsvetina; Ulrich, Sarah et al.
Intermediate outcomes of transcatheter pulmonary valve replacement with the Edwards Sapien 3 valve - German experienceEXPERT REVIEW OF MEDICAL DEVICES. Bd. 16. H. 9. 2019 S. 829-834
Lehner, Anja; Dashkalova, Tsvetina; Ulrich, Sarah et al.
Intermediate outcomes of transcatheter pulmonary valve replacement with the Edwards Sapien 3 valve - German experienceEXPERT REVIEW OF MEDICAL DEVICES. 2019
Maher, E. R.; Brioude, F.; Kalish, J. M. et al.
International consensus group statement on Beckwith-Wiedemann syndromeEUROPEAN JOURNAL OF HUMAN GENETICS. Bd. 27. 2019 S. 346-347
Wagner, Norbert; Zepp, Fred
Laudation for the 60th Birthday of Prof. Dr. med. Michael WeissMONATSSCHRIFT KINDERHEILKUNDE. Bd. 167. H. 10. 2019 S. 946-947
Graef, Christine; Hoffmann, Isabell; Diefenbach, Christiane et al.
Mental health problems and school performance in first graders: results of the prospective cohort study ikidSEUROPEAN CHILD & ADOLESCENT PSYCHIATRY. Bd. 28. H. 10. 2019 S. 1341-1352
Meyer, C. U.; Klopp, J.; Knoll, R. L. et al.
Modulation of the microbiome by probiotics in pediatric practise. Sense or nonsense?MONATSSCHRIFT KINDERHEILKUNDE. Bd. 167. H. 5. 2019 S. 389-395
Pena, Loren; Barohn, Richard J.; Dimachkie, Mazen M. et al.
NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patientsMOLECULAR GENETICS AND METABOLISM. Bd. 126. H. 2. 2019 S. S115-S116
Dimachkie, Mazen M.; Barohn, Richard J.; Kishnani, Priya S. et al.
NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe DiseaseNEUROLOGY. Bd. 92. H. 15. 2019
Schoser, B.; Barohn, R.; Dimachkie, M. et al.
NEO1 and NEO-EXT studies: pharmacodynamic and exploratory biomarker assessments following repeat avalglucosidase alfa dosing for up to 4.5 years in patients with late-onset Pompe diseaseEUROPEAN JOURNAL OF NEUROLOGY. Bd. 26. 2019 S. 326-326
Dimachkie, Mazen; Barohn, Richard; Kishnani, Priya et al.
NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASEMUSCLE & NERVE. Bd. 60. 2019 S. S48-S49